Abstract |
c-MYC (hereafter MYC) overexpression has been recognized in aggressive B-cell lymphomas and linked to adverse prognosis. MYC activation results in widespread repression of micro-RNA ( miRNA) expression and associated with lymphoma aggressive progression. Our recent study identified a MYC-miRNA-EZH2 feed-forward loop linking overexpression of MYC, EZH2 and miRNA repression. Here, using a novel small-molecule BET bromodomain inhibitor, JQ1, and the EZH2 inhibitor, DZNep, we demonstrated that combined treatment of JQ1 and DZNep cooperatively disrupted MYC activation, resulting in a greater restoration of miR-26a expression and synergistically suppressed lymphoma growth and clonogenicity in aggressive lymphoma cells. Furthermore, CHIP assay demonstrated that MYC recruited EZH2 to miR-26a promoter and cooperatively repressed miR-26a expression in aggressive lymphoma cell lines, as well as primary lymphoma cells. Loss- or gain-of-function approaches revealed that miR-26a functioned as a tumor suppressor miRNA and mediated the combinatorial effects of JQ1 and DZNep. These findings represent a novel promising approach for silencing MYC-miRNA-EZH2 amplification loop for combinatorial therapy of aggressive B-cell lymphomas.
|
Authors | X Zhao, T Lwin, X Zhang, A Huang, J Wang, V E Marquez, S Chen-Kiang, W S Dalton, E Sotomayor, J Tao |
Journal | Leukemia
(Leukemia)
Vol. 27
Issue 12
Pg. 2341-50
(Dec 2013)
ISSN: 1476-5551 [Electronic] England |
PMID | 23538750
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- DNA Primers
- MicroRNAs
- EZH2 protein, human
- Enhancer of Zeste Homolog 2 Protein
- Polycomb Repressive Complex 2
|
Topics |
- Base Sequence
- Cell Line, Tumor
- DNA Primers
- Enhancer of Zeste Homolog 2 Protein
- Genes, myc
- Humans
- Lymphoma, B-Cell
(genetics, pathology)
- MicroRNAs
(genetics)
- Polycomb Repressive Complex 2
(genetics)
- Promoter Regions, Genetic
|